The world’s largest DNA sequencing company says it will form a new company to develop blood tests that cost $1,000 or less and can detect many types of cancer before symptoms arise.
Illumina, based in San Diego, said its blood tests should reach the market by 2019, and would be offered through doctors’ offices or possibly a network of testing centers.
Deloitte today announced a strategic alliance agreement with AT&T aimed at accelerating the adoption of smart city technology across U.S. cities. The telco and global management consultancy, along with several other hand-picked alliance members, strive to enhance livability and improve the efficiencies of local governments through optimal use of today’s technology.
Six startups have been selected for the Emerging Technology Centers’ AccelerateBaltimore program and one will receive an extra investment of $100,000. Now in its fifth year, AccelerateBaltimore is a four month program that aims to help promising startup companies come closer to bringing their products or services to market. The program is backed by $170,000 from the Abell Foundation. The money largely goes toward the $25,000 award given to each participating company.
OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.
Guy Marcus, a 24-year-old Ph.D. candidate in physics at the Johns Hopkins University, is one of 30 young scientists named to Forbes magazine’s annual “30 Under 30” list.
As usual, we bring you the top five entries from our most recent list. This week, it’s the top venture capital recipients in Maryland, based on funding received between the first and third quarters of 2015.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
David Narrow, who graduated from Johns Hopkins University in 2013 with a master’s degree in biomedical engineering, has been named one of Forbes magazine’s “30 Under 30” notable entrepreneurs in the health care industry.
Narrow, 25, is the CEO of Sonavex, a company that works to improve outcomes for surgical patients by providing clinicians cutting-edge visualization through the use of imaging technology. Sonavex is presently based in North Baltimore and is part of FastForward at Johns Hopkins Technology Ventures, a business accelerator program that supports startup companies.
Accelerator Corporation, a leading life science investment and management firm, today announced the Series A financing of Petra Pharma Corporation to develop small molecule inhibitors for the treatment of cancer and metabolic diseases in alliance with Weill Cornell Medicine. The investors participating in the $48 million Series A investment in Petra Pharma include Accelerator New York’s investment syndicate partners: AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Inc., Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., The Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund and WuXi PharmaTech.
Under Armour’s partnership with IBM Watson is the latest in a series of announcements from the consumer health and fitness business that illustrate how the company is thinking about big data applications not only to provide timely, helpful insights on athletic training to a customer base of 180 million but also how to get them to buy more gear.
